Sugammadex: a novel approach to reversal of neuromuscular blockade

References

• Beecher HK, Todd DP. A study of deaths associated with anesthesia and surgery: based on a study of 599,548 anesthesias in ten institutions 1948–1952, inclusive. Ann. Surg.140, 2–35 (1954).
   PubMed Web of Science ®Google Scholar
• Harrison GG. Death attributable to anaesthesia. A 10-year survey (1967–1976). Br. J. Anaesth.50(10), 1041–1046 (1978).
   PubMedGoogle Scholar
• Dam WH, Guldmann N. Inadequate postanesthetic ventilation. Curare, anesthetic, narcotic, diffusion hypoxia. Anesthesiology22, 699–707 (1961).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth. Analg.107(1), 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Debaene B, Plaud B, Dilly MP et al. Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology98(5), 1042–1048 (2003).
   PubMed Web of Science ®Google Scholar
• Yip PC, Hannam JA, Cameron AJ et al. Incidence of residual neuromuscular blockade in a post-anaesthetic care unit. Anaesth. Intensive Care38(1), 91–95 (2010).
   PubMedGoogle Scholar
• Bom A, Bradley M, Cameron K et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew. Chem. Int. Ed. Engl.41, 266–270 (2002).
   PubMed Web of Science ®Google Scholar
• Adam JM, Bennett DJ, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure–activity relationships. J. Med. Chem.45(9), 1806–1816 (2002).
   PubMed Web of Science ®Google Scholar
• Buzello W, Schluermann D, Schindler M, Spillner G. Hypothermic cardiopulmonary bypass and neuromuscular blockade by pancuronium and vecuronium. Anesthesiology62, 201–204 (1985).
   PubMedGoogle Scholar
• Denny NM, Kneeshaw JD. Vecuronium and atracurium infusions during hypothermic cardiopulmonary bypass. Anaesthesia41, 919–922 (1986).
   PubMedGoogle Scholar
• Atherton DP, Hunter JM. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin. Pharmacokinet.36(3), 169–189 (1999).
   PubMed Web of Science ®Google Scholar
• Miller RD, Ward TA. Monitoring and pharmacologic reversal of a nondepolarizing neuromuscular blockade should be routine. Anesth. Analg.111(1), 3–5 (2010).
   PubMedGoogle Scholar
• Hazizaj A, Hatija A. Bronchospasm caused by neostigmine. Eur. J. Anaesthesiol.23, 85–86 (2006).
   PubMedGoogle Scholar
• Sprague DH. Severe bradycardia after neostigmine in a patient taking propranolol to control paroxysmal atrial tachycardia. Anesthesiology42, 208–210 (1975).
   PubMedGoogle Scholar
• Beebe DS, Shumway SJ, Maddock R. Sinus arrest after intravenous neostigmine in two heart transplant recipients. Anesth. Analg.78, 779–782 (1994).
   PubMedGoogle Scholar
• Bell CM, Lewis CB. Effect of neostigmine on integrity of ileorectal anastomoses. Br. Med. J.3(5618), 587–588 (1968).
   PubMedGoogle Scholar
• Bartowski RR. Incomplete reversal of pancuronium neuromuscular blockade by neostigmine, pyridostigmine, and edrophonium. Anesth. Analg.66, 594–598 (1987).
   PubMedGoogle Scholar
• Kopman AF, Yee PS, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology86, 765–771 (1997).
   PubMed Web of Science ®Google Scholar
• El Mikatti N, Wilson A, Pollard BJ, Healy TE. Pulmonary function and head lift during spontaneous recovery from pipecuronium neuromuscular block. Br. J. Anaesth.74, 16–19 (1995).
   PubMedGoogle Scholar
• Sundman E, Witt H, Olsson R et al. The incidence and mechanisms of pharyngeal and upper esophageal dysfunction in partially paralyzed humans: pharyngeal videoradiography and simultaneous manometry after atracurium. Anesthesiology92(4), 977–984 (2000).
   PubMed Web of Science ®Google Scholar
• Eriksson LI, Sundman E, Olsson R et al. Functional assessment of the pharynx at rest and during swallowing in partially paralyzed humans: simultaneous videomanometry and mechanomyography of awake human volunteers. Anesthesiology87, 1035–1043 (2000).
   Google Scholar
• Capron F, Fortier LP, Racine S, Donati F. Tactile fade detection with hand and wrist stimulation using train-of-four, double-burst stimulation, 50-hertz tetanus, 100-hertz tetanus, and acceleromyography. Anesth. Analg.102(5), 1578–1584 (2006).
   PubMedGoogle Scholar
• Viby-Mogensen J, Jensen NH, Engbaek J et al. Tactile and visual evaluation of the response to train-of-four nerve stimulation. Anesthesiology63, 440–443 (1985).
   PubMedGoogle Scholar
• Trager G, Michaud G, Deschamps S, Hemmerling TM. Comparison of phonomyography, kinemyography, and mechanomyography for neuromuscular monitoring. Can. J. Anaesth.53, 130–135 (2006).
   PubMed Web of Science ®Google Scholar
• Naguib M, Kopman AF, Lien CA et al. A survey of current neuromuscular practice in the United States and Europe. Anesth. Analg.111, 110–119 (2010).
   PubMed Web of Science ®Google Scholar
• Yip PC, Hannam JA, Cameron AJ, Campbell D. Incidence of residual neuromuscular blockade in a post-anaesthetic care unit. Anaesth. Intensive Care38, 91–95 (2010).
   PubMedGoogle Scholar
• Claudius C, Karacan H, Viby-Mogensen J. Prolonged residual paralysis after a single intubating dose of rocuronium. Br. J. Anaesth.99, 514–517 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy GS, Szokol JW, Marymont JH et al. Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth. Analg.107, 130–137 (2008).
   PubMed Web of Science ®Google Scholar
• Bissinger U, Schimek F, Lenz G. Postoperative residual paralysis and respiratory status: a comparative study of pancuronium and vecuronium. Physiol. Res.49, 455–462 (2000).
   PubMed Web of Science ®Google Scholar
• Mathew JP, Rosenbaum SH, O’Connor T, Barash PG. Emergency tracheal intubation in the postanesthesia care unit: physician error or patient disease? Anesth. Analg.71, 691–697 (1990).
   PubMedGoogle Scholar
• Murphy GS, Szokol JW, Franklin M et al. Postanesthesia care unit recovery times and neuromuscular blocking drugs: a prospective study of orthopedic surgical patients randomized to receive pancuronium or rocuronium. Anesth. Analg.98, 193–200 (2004).
   PubMed Web of Science ®Google Scholar
• Szerman N, Schroh I, Rossi AL, Rosso AM, Krymkiewicz N, Ferrarotti SA. Cyclodextrin production by cyclodextrin glycosyltransferase from Bacillus circulans DF 9R. Bioresour. Technol.98, 2886–2891 (2007).
   PubMedGoogle Scholar
• Adam JM, Bennett J, Bom A et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J. Med. Chem.45, 1806–1816 (2002).
   PubMed Web of Science ®Google Scholar
• Tarver GJ, Grove SJ, Buchanan K, Bom A. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg. Med. Chem.10, 1819–1827 (2002).
   PubMedGoogle Scholar
• Naguib M, Brull SJ. Sugammadex: a novel selective relaxant binding agent. Expert Rev. Clin. Pharmacol.2, 37–53 (2009).
   PubMedGoogle Scholar
• de Boer HD, van Egmond J, van de Pol F et al. Chemical encapsulation of rocuronium by synthetic cyclodextrin derivatives: reversal of neuromuscular block in anaesthetized Rhesus monkeys. Br. J. Anaesth.96, 201–206 (2006).
   PubMedGoogle Scholar
• Sorgenfrei IF, Norrild K, Larsen PB et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology104, 667–674 (2006).
   PubMed Web of Science ®Google Scholar
• Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology103, 695–703 (2005).
   PubMed Web of Science ®Google Scholar
• Staals LM, Snoeck MM, Driessen JJ et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br. J. Anaesth.104, 31–39 (2010).
   PubMed Web of Science ®Google Scholar
• Cammu G, de Kam PJ, Demeyer I et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br. J. Anaesth.100, 373–379 (2008).
   PubMed Web of Science ®Google Scholar
• Shields M, Giovannelli M, Mirakhur RK et al. Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br. J. Anaesth.96, 36–43 (2006).
   PubMed Web of Science ®Google Scholar
• Suy K, Morias K, Cammu G et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology106, 283–288 (2007).
   PubMed Web of Science ®Google Scholar
• de Boer HD, Driessen JJ, Marcus MA et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose finding and safety study. Anesthesiology107, 239–244 (2007).
   PubMed Web of Science ®Google Scholar
• Groudine SB, Soto R, Lien C, Drover D, Roberts K. A randomized, dose-finding, Phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth. Analg.104, 555–562 (2007).
   PubMed Web of Science ®Google Scholar
• Sparr HJ, Vermeyen KM, Beaufort AM et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology106, 935–943 (2007).
   PubMed Web of Science ®Google Scholar
• Vanacker BF, Vermeyen KM, Struys MM et al. Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth. Analg.104, 563–568 (2007).
   PubMed Web of Science ®Google Scholar
• Puhringer FK, Rex C, Sielenkämper AW et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding safety assessor-blinded, Phase II trial. Anesthesiology109, 188–197 (2008).
   PubMed Web of Science ®Google Scholar
• Rex C, Wagner S, Spies C et al. Reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients randomized to sevoflurane or propofol maintenance anesthesia. Anesthesiology111, 30–35 (2009).
   PubMed Web of Science ®Google Scholar
• Dahl V, Pendeville PE, Hollmann MW et al. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur. J. Anaesthesiol.26, 874–884 (2009).
   PubMed Web of Science ®Google Scholar
• Duvaldestin P, Kuizenga K, Saldien V et al. A randomized, dose–response study of sugammadex given for the reversal of deep rocuronium- or vecuronium-induced neuromuscular blockade under sevoflurane anesthesia. Anesth. Analg.110, 74–82 (2010).
   PubMed Web of Science ®Google Scholar
• Vasella FC, Frascarolo P, Spahn DR, Magnusson L. Antagonism of NMB but not muscle relaxation affects depth of anaesthesia. Br. J. Anaesth94, 742–747 (2005).
   PubMedGoogle Scholar
• Lanier WL, Iaizzo PA, Milde JH, Sharbrough FW. The cerebral and systemic effects of movement in response to a noxious stimulus in lightly anesthetized dogs. Possible modulation of cerebral function by muscle afferents. Anesthesiology80, 392–401 (1994).
   PubMedGoogle Scholar
• de Kam PJ, van Kuijk J, Prohn M, Thomsen T, Peeters P. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study. Clin. Drug Investig.30, 599–611 (2010).
   PubMed Web of Science ®Google Scholar
• de Kam PJ, van Kuijk J, Smeets J et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology107, A1580 (2007).
   Google Scholar
• Peeters P, Passier P, Smeets J, van Iersel T. Single intravenous high-dose sugammadex (up to 96 mg/kg) is generally safe and well tolerated in healthy volunteers. Eur. J. Anaesthesiol.25, 9AP3–6 (2008).
   Google Scholar
• Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. Br. J. Anaesth.101, 492–497 (2008).
   PubMed Web of Science ®Google Scholar
• Plaud B, Meretoja O, Hofmockel R et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology110, 284–294 (2009).
   PubMed Web of Science ®Google Scholar
• McDonagh DL, Benedict PE, Kovac AL et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology107, A1583 (2007).
   Web of Science ®Google Scholar
• Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium–atropine. Anesth. Analg.104, 569–574 (2007).
   PubMed Web of Science ®Google Scholar
• Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: a randomized comparison with neostigmine. Anesthesiology109, 816–824 (2008).
   PubMed Web of Science ®Google Scholar
• Flockton EA, Mastronardi P, Hunter JM et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br. J. Anaesth.100(5), 622–630 (2008).
   PubMed Web of Science ®Google Scholar
• Blobner M, Eriksson LI, Scholz J et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomized, controlled trial. Eur. J. Anaesthesiol.27, 874–881 (2010).
   PubMed Web of Science ®Google Scholar
• Lemmens HJ, El-Orbany MI, Berry J, Martin G. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine. Anesthesiology107, A1578 (2007).
   Google Scholar
• Blobner M, Eriksson L, Scholz J, Hillebrand H, Pompei L. Sugammadex (2.0 mg/kg) reverses shallow rocuronium-induced neuromuscular blockade significantly faster compared with neostigmine (50 µg/kg). Eur. J. Anaesthesiol.24(Suppl. 39), 9AP7–10 (2007).
   Google Scholar
• Alvarez-Gomez JA, Wattwill M, Vanacker B et al. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine. Eur. J. Anaesthesiol.124, 9AP7–8 (2007).
   Google Scholar
• Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth. Analg.110, 64–73 (2010).
   PubMed Web of Science ®Google Scholar
• Amao R, Zornow MH, Cowan RM et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease. Anesthesiology107, A1582 (2007).
   Google Scholar
• Molina AL, de Boer HD, Klimek M et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by accidental high dose of sugammadex (40 mg/kg). Br. J. Anaesth.98, 624–627 (2007).
   PubMedGoogle Scholar
• Brull SJ, Murphy GS. Residual neuromuscular block: lessons unlearned. Part II: methods to reduce the risk of residual weakness. Anesth. Analg.111, 129–140 (2010).
   PubMed Web of Science ®Google Scholar
• Savarese JJ, McGilvra JD, Sunaga H et al. Rapid chemical antagonism of neuromuscular blockade by L-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinolinium diester compounds gantacurium (AV430A), CW 002, and CW 011. Anesthesiology113(1), 58–73 (2010).
   PubMed Web of Science ®Google Scholar
• Lee C, Jahr JS, Candiotti KA et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology110, 1020–1025 (2009).
   PubMed Web of Science ®Google Scholar
• Decoopman M, Cammu G, Suy K, Heeringa M. Reversal of pancuronium-induced block by the selective relaxant binding agent sugammadex. Eur. J. Anaesthesiol.24, 9AP2–1 (2007).
   Google Scholar
• Pavlin EG, White PF, Viegas OJ et al. Sugammadex given at least 15 minutes after rocuronium is effective in reversing neuromuscular blockade. Anesthesiology17, A1579 (2007).
   Google Scholar